Toprol XL Articles
AstraZeneca beats consensus forecasts with 3rd quarter 2009 profits up 22% raises forecasts
29 October 2009
AZ restores Toprol-XR supply
19 May 2009
Watson's 2nd-qtr 2008 profit jumps 66%
18 August 2008
Watson's 1st-qtr 2008 net income jumps 60%
12 May 2008
KV's fiscal 3rd-qtr net revenue jumps 39%
17 March 2008
Watson swings to profit of $38.4M in 4th qtr
3 March 2008
Par's 3rd qtr net falls 70% on Strativa costs
14 January 2008
KV reports record sales in 2nd-qtr fiscal 2008
10 December 2007
Sandoz debut generic Toprol in USA
13 August 2007
Sandoz gains FDA appro for generic Toprol
28 May 2007
Stock Commentary - Europe - week to Nov 27
4 December 2006
AstraZeneca authorizes US generic Toprol-XL
27 November 2006
AstraZeneca's offer to Medicare Part D enrollees
20 November 2006
Rx price rise at "double inflation" says AARP
17 April 2006
AstraZeneca may pay Merck & Co $3.3B
20 March 2006
AstraZeneca appeals Toprol XL patent loss
27 February 2006
AstraZeneca profit leaps 30% but firm admits thin pipeline
6 February 2006
Stock Commentary - Europe - week to Jan 23
30 January 2006
Stock Commentary - New York week to Nov 28
5 December 2005
USA
22 August 2005
KV Pharma's fiscal 2005 sees 7% sales rise
20 June 2005
AstraZeneca sues KV Pharma over Toprol-XL patent
27 September 2004
AstraZeneca sues Eon Labs over metoprolol patents
12 April 2004
AstraZeneca sues Andrx over metoprolol patents
16 February 2004
AstraZeneca files suit to protect Toprol XL
12 May 2003
AstraZeneca's Toprol XL challenged by KV Pharm
14 April 2003
AstraZeneca begins REVERT trial
31 August 2001
AstraZeneca's Toprol-XL cleared for CHF in USA
5 April 2001
Beta Blockers Show Further Value In Heart Failure
18 November 1998
Astra Pulls Out Of Bextra Collaboration
1 October 1998
Intercardia May Drop Astra As Bextra Partner
6 August 1998
LOSEC SALES ROCKET FOR ASTRA
25 May 1992
US APPROVAL FOR ASTRA's TOPROL XL
20 January 1992
Showing 1-35 of 35 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
